Bafna Pharmaceuticals, a Chennai-based pharma company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non-Betalactum, received approval from Ghana Food and Drug Administration (FDA) to market Omeran -20 capsules (Gastro - Resistant Omeprazole Capsules 20mg) , a proton pump inhibitor used in the treatment of reflux oesophagitis, peptic ulcer disease (PUD), Gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.

The drug contains generic salt - Omeprazole and its International Classification of Diseases is Omeprazole. With this, Bafna now has 15 number of formulation approvals from Ghana FDA for products of Bafna Pharmaceuticals.

Mr. Mahaveer Bafna, Chairman and Managing Director, Bafna Pharmaceuticals said, "This is a major milestone for Bafna Pharmaceuticals. It will strengthen our market in Ghana and helps us in penetrating in our target market segment. We have already received product approval from Ghana FDA in the past and with the entry of Omeran, it has added a new feather in the cap."

Bafna is already present in Ghana with FDA approvals including, Atenolol 50 mg and Atenolol 100 mg tablets, Metformin tablets BP 500mg, Fluconazole tablets 150 mg, Iron tonic fortified with protein, folic acid, Vitamin B12 and Zinc syrup, Haematinic capsules with Vitamins and Zinc, Azithromycin tablets 250mg, Azithromycin tablets 500 mg, Amlodipine Besilate tablets 5mg and Amlodipine Besilate tablets 10 mg, Diclofenac Sodium, Paracetamol and Chlorzoxazone Tablets, Glibenclamide Tablets 5mg, Azithromycin Suspension, Iron with Folic Acid Capsules.

The company has recently announced its standalone sales turnover of Rs 27.79 crore and a net profit of Rs 1.41 crore for the quarter Dec '12, Other income for the quarter was Rs 0.52 crore. For the quarter Dec 2011 the standalone sales turnover was Rs 21.07 crore and net profit was Rs 1.77 crore and other income Rs 0.61 crore.